Tamara Levin Lotan, M.D.

Headshot of Tamara Levin Lotan
  • Acting Director of Urologic Pathology, The Johns Hopkins Hospital
  • Professor of Pathology

Expertise

Pathology, Prostate Cancer

Research Interests

Prostate cancer; Bladder cancer

Locations

The Johns Hopkins Hospital (Main Entrance)

1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-955-9790
The Johns Hopkins Hospital (Main Entrance) - Google Maps

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue
Baltimore, MD 21224
Phone: 410-955-9790
Johns Hopkins Bayview Medical Center - Google Maps

Johns Hopkins Outpatient Center (now called Levi Watkins, Jr., M.D., Outpatient Center)

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

401 N. Broadway
Baltimore, MD 21231
Phone: 410-955-9790 | Fax: 410-502-9911
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Google Maps

Background

Dr. Tamara Lotan is an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine. Her area of clinical expertise is urologic pathology.

Dr. Lotan received her medical degree from the University of Chicago Pritzker School of Medicine. She completed her residency in anatomic pathology at the University of Chicago Hospitals and performed a fellowship in Urologic Pathology at the Johns Hopkins University School of Medicine.

She is a urologic pathologist who studies how oncogenic signaling pathways regulate epithelial morphogenesis during embryonic development and tumorigenesis. Her basic research focuses on the role of PTEN/PI3K/mTOR signaling in a number of epithelial systems (prostate, breast, skin), and is principally directed towards understanding how these oncogenic signaling pathways affect epithelial differentiation, cell adhesion and migration using transgenic mouse models. The translational research program in her lab has centered on the analytic, pre-analytic and clinical validation of a number of prognostic and/or predictive tissue-based biomarkers in prostate cancer. 

Dr. Lotan was recognized by the Prostate Cancer Foundation with the 2011 Elaine Wynn – PCF Young Investigator Award. She is a member of the United States and Canadian Academy of Pathology, the College of American Pathology, and the International Society of Urologic Pathology. 

Dr. Lotan is engaged in research training and is the Associate Director of the Pathobiology graduate program at Johns Hopkins.

 

...read more

Titles

  • Acting Director of Urologic Pathology, The Johns Hopkins Hospital
  • Professor of Pathology
  • Joint Appointment in Urology
  • Professor of Oncology

Departments / Divisions

  • Oncology - Genitourinary Cancer Disease
  • Pathology - Kidney-Urologic Pathology
  • Urology

Centers & Institutes

Education

Degrees

  • MD; University of Chicago Pritzker School of Medicine (2003)

Residencies

  • Anatomic Pathology; University of Chicago Medicine (2005)
  • Anatomic Pathology; University of Chicago Medicine (2007)

Fellowships

  • Pathology; Johns Hopkins University School of Medicine (2008)

Board Certifications

  • American Board of Pathology (Anatomic Pathology) (2007)

Research & Publications

Research Summary

Dr. Tamara Lotan is a urologic pathologist who studies how oncogenic signaling pathways regulate epithelial morphogenesis during embryonic development and tumorigenesis. Using novel transgenic mouse models combined with human tumor tissue samples, Dr. Lotan is defining the roles of these critical signals in epithelial development and tumor progression.

Selected Publications

View all on PubMed

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM. PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research 2011; 17(20):6563-73.

Tan H, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, Liu W, Isaacs WB, De Marzo AM, Lotan TL. Rb Loss is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. Clinical Cancer Research 2014; 20(4):890-903.

Ahearn TU, PetterssonA, Ebot EM, Gerke T, Morais CL, Hicks J, Wilson KM, RiderJR, Sesso HD,Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA*, Lotan TL*. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. JNCI 2016; 108(2). *Equal Contribution

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks JL, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL. MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research 2017; 23(22):6863-6874.

Asrani K, Sood A, Torres A, Georgess D, Phatak P, Kaur H, Dubin A, Talbot CC Jr, Elhelu L, Ewald AJ, Xiao B, Worley P, Lotan TL. mTORC1 Loss Impairs Epidermal Adhesion via TGF-β/Rho kinase activation. Journal of Clinical Investigation 2017; 127(11):4001-4017.

Activities & Honors

Honors

  • Elaine Wynn Young Investigator Award, PCF , 2011

Memberships

  • College of American Pathology
  • International Society of Urologic Pathology
  • United States and Canadian Academy of Pathology
Is this you? Edit Profile
back to top button